Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.

Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN guidelines for select patients with previously treated breast cancer.

Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.

The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.